<DOC>
	<DOCNO>NCT00547378</DOCNO>
	<brief_summary>The purpose study : 1 . To provide evidence randomize control trial InterStim Therapy provide good relief symptom OAB standard medical treatment current use . 2 . To fulfill requirement FDA-mandated post-approval study safety tin lead use minimally invasive approach .</brief_summary>
	<brief_title>InSite Over Active Bladder</brief_title>
	<detailed_description>Approximately 30 million Americans meet criterion overactive bladder ( OAB ) . Urinary void dysfunction symptom impose significant physical psychosocial impact individual , include loss self-esteem decrease ability maintain independent lifestyle . These symptom substantially affect subject 's daily activity . Patients OAB manage diet modification , bladder training retraining , pelvic muscle rehabilitation , medication biofeedback . Medications use first-line therapy urgency frequency urinary urge incontinence . InterStim Therapy utilize sacral nerve stimulation indicate US treatment urinary retention symptom OAB , include urinary urge incontinence significant symptom urgency-frequency alone combination , subject fail could tolerate conservative treatment . InSite OAB Protocol 1634 consist two phase ; Phase I randomize portion trail Phase II non-randomized portion . Phase 1 : A minimum 60 subject randomize InterStim minimum 60 subject randomize SMT . Phase 2 : Non-randomized , qualified subject receive InterStim , approximately 297 enrolled Subjects previously enrol Protocol 1634 Urinary Urge Incontinence Protocol 1635 Urgency-Frequency include Phase I new Protocol 1634 OAB .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Have diagnosis OAB include urinary urge incontinence urgencyfrequency Be male female least 18 year age old Be able consent participate signing Informed Consent Be willing able attend visit comply study protocol include adequate operation equipment Have fail candidate conservative treatment ( e.g . pelvic floor training , biofeedback , behavioral modification ) Have fail could tolerate ( stopped take medication due lack efficacy intolerable side effect ) least one anticholinergic antimuscarinic medication AND least one anticholinergic antimuscarinic medication yet attempt Have current regiment OAB medication OAB medication , least 4 week prior begin baseline void diary Have severe uncontrolled diabetes diabetes peripheral nerve involvement Have concomitant medical condition would limit success study procedure Have skin , orthopedic neurologic anatomical limitation could prevent successful placement electrode Have neurological disease multiple sclerosis , clinically significant peripheral neuropathy complete spinal cord injury ( e.g. , paraplegia ) Have knowledge plan MRIs , diathermy , microwave exposure , high output ultrasonic exposure , RF energy exposure Have urinary tract mechanical obstruction benign prostatic hypertrophy , cancer , urethral stricture Have symptomatic urinary tract infection ( UTI ) Have implantable neurostimulators , pacemaker , defibrillator Have primary stress incontinence mixed incontinence stress component override urge component Have treatment urinary symptom botulinum toxin therapy past 12 month Be woman pregnant planning become pregnant woman childbearing potential use medicallyacceptable method birth control Have life expectancy le one year Have plan enroll another investigation device drug trial participation trial , currently enrol investigational device drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>overactive bladder , urinary incontinence , incontinence , Urgency-frequency</keyword>
</DOC>